Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotechnology company focused on developing allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune diseases, has announced its participation in two upcoming investor conferences:

1. Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024, at 7:00 AM PT/10:00 AM ET

2. Baird 2024 Global Healthcare Conference on Wednesday, September 11, 2024, at 7:15 AM PT/10:15 AM ET

Webcasts, if available, will be accessible on the company's website at www.allogene.com under the Investors tab in the News and Events section. Replays will be available for approximately 30 days after the live webcasts.

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in two upcoming investor conferences in August and September.

Canaccord Genuity 44^th Annual Growth Conference
Tuesday, August 13, 2024
7:00AM PT/10:00AM ET

Baird 2024 Global Healthcare Conference
Wednesday, September 11, 2024
7:15AM PT/10:15AM ET

Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T^™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X (formerly Twitter) and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factor” heading in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com

FAQ

When is Allogene Therapeutics (ALLO) participating in the Canaccord Genuity Growth Conference?

Allogene Therapeutics (ALLO) is participating in the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024, at 7:00 AM PT/10:00 AM ET.

What is the date for Allogene Therapeutics' (ALLO) presentation at the Baird Global Healthcare Conference?

Allogene Therapeutics (ALLO) is presenting at the Baird 2024 Global Healthcare Conference on Wednesday, September 11, 2024, at 7:15 AM PT/10:15 AM ET.

Where can investors find webcasts of Allogene Therapeutics' (ALLO) conference presentations?

Investors can find webcasts of Allogene Therapeutics' (ALLO) conference presentations on the company's website at www.allogene.com under the Investors tab in the News and Events section.

How long will replays of Allogene Therapeutics' (ALLO) conference webcasts be available?

Replays of Allogene Therapeutics' (ALLO) conference webcasts will be available on the company's website for approximately 30 days after the live events.

What types of products is Allogene Therapeutics (ALLO) developing?

Allogene Therapeutics (ALLO) is developing allogeneic CAR T (AlloCAR T™) products for the treatment of cancer and autoimmune diseases.